MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Kick Out PD: Mobility, Quality of Life, and Feasibility Outcomes in a Pilot Study of a PD-Specific Karate Intervention

    B. Sennott, C. Niemet, M. Lee, C. Whitelock, M. Sanghvi, Y. Liu, J. Chodosh, D. Hall, C. Comella, J. Fleisher (Chicago, IL, USA)

    Objective: To evaluate feasibility of a community-based karate class tailored for individuals with early- to middle-stage Parkinson’s Disease (PD); to assess effect of karate on…
  • 2019 International Congress

    Predicting the efficacy of STN-DBS in patients with different Parkinson’s disease motor subtypes by preoperative total and partial levodopa response

    GH. Lu, ZX. Yin, YW. Jin (Nanchang, China)

    Objective: To better investigate the value of the challenge test by introducing total and partial LR, and explain the clinical significance of 30% LR through…
  • 2019 International Congress

    Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

    M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)

    Objective: To assess the local and systemic safety and tolerability of ABBV-951 delivered as a continuous subcutaneous infusion (CSCI) for 24 hours daily for up…
  • 2019 International Congress

    Safinamide: real world evidence in Toledo´s Movement Disorders Unit

    N. López-Ariztegui, MI. Morales-Casado, JC. Segundo-Rodríguez, A. Avila-Fernández, N. García-Alvarado, J. Pérez-Matos (Toledo, Spain)

    Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…
  • 2019 International Congress

    Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

    M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

    Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…
  • 2019 International Congress

    Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment

    B. Kennedy, J. Peterson, D. Charles (Washington, DC, USA)

    Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…
  • 2019 International Congress

    Tremor and parkinsonism in Chromosomopathies – a systematic review

    V. Carvalho, L. Guedes (Matosinhos, Portugal)

    Objective: To review the co-occurrence of parkinsonism and tremor syndromes in patients with chromosomic disorders. Background: The landscape of genetic forms of Parkinson’s diseases (PD)…
  • 2019 International Congress

    The potential modifier effect of C9orf72 DNA methylation in C9ORF72 carriers

    JM. Laffita-Mesa, CH. Kreidy, M. Paucar, P. Svenningsson (Stockholm, Sweden)

    Objective: To develop molecular assays for determining the influence of hypermethylation on age of onset for C9ORF72 carriers. Background: Hexanucleotide repeats of GGGGCC in C9ORF72 is…
  • 2019 International Congress

    Serum MIR-96-5P and MIR-339-5P as a Potential Biomarker for Multiple System Atrophy and Parkinson’s Disease

    A. Vallelunga, T. Iannitti, S. Capece, G. Somma, G. Dati, P. Barone, W. Meissner, M. Pellecchia (Salerno, Italy)

    Objective: The aim of our study was to to determine if serum mir-96-5p and mir-339-5p can be used as biomarkers for early diagnosis of Parkinson’s…
  • 2019 International Congress

    Hypophosphatasia presenting as parkinsonism with compound heterozygous mutations in ALPL gene

    WF. Yu, ZX. Zhao, LW. Liu, JL. Hu, FF. Wang, YM. Liu (Jinan, China)

    Objective: We report a hypophosphatasia patient presenting as parkinsonism, characterized by compound heterozygous mutations in ALPL gene. Background: Hypophosphatasia (HPP) is a rare metabolism disease,…
  • « Previous Page
  • 1
  • …
  • 159
  • 160
  • 161
  • 162
  • 163
  • …
  • 425
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley